ACTRN12613000002785
8 evidence topics · 1 source
Objective
Exposure objective
Location and study date
No evidence found.
Study design
Repeated-dose regimen
Eligibility criteria
Treatment
Regimen duration
| Characteristic | Quoted value |
|---|---|
| Treatment period | “25-day” |
Study outcomes
Rationale for using plasma cytisine concentrations as the pharmacokinetic endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Participants
| Characteristic | Quoted value |
|---|---|
| Study sample | “10” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Accumulation after repeated dosing
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Reported adverse effects
Study limitations
Summary
The pharmacokinetic study included 10 healthy adult smokers and used the standard 25-day regimen. It provides evidence of accumulation but cannot establish clinical cessation efficacy or detect uncommon harms.